UNITÉ DE FABRICATION DES MÉDICAMENTS S.A |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.17 TND | -0.14% |
|
-0.69% | -4.14% |
| Sales 2023 * | 134M 42.82M | Sales 2024 * | 141M 45.06M | Capitalization | 229M 73.32M |
|---|---|---|---|---|---|
| Net income 2023 * | 16M 5.11M | Net income 2024 * | 18M 5.75M | EV / Sales 2023 * | 2.17 x |
| Net Debt 2023 * | 61.1M 19.52M | Net Debt 2024 * | 66.6M 21.28M | EV / Sales 2024 * | 2.1 x |
| P/E ratio 2023 * |
12.4
x | P/E ratio 2024 * |
11.6
x | Employees | 572 |
| Yield 2023 * |
6.97% | Yield 2024 * |
7.67% | Free-Float | 29.98% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.14% | ||
| 1 week | -0.69% | ||
| Current month | -0.42% | ||
| 1 month | -2.45% | ||
| 3 months | -0.42% | ||
| 6 months | -8.08% | ||
| Current year | -4.14% |
1 week
7.12
7.25
1 month
7.127.39
Current year
6.927.56
1 year
6.858.28
3 years
6.618.28
5 years
6.6110.95
10 years
6.6111.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 88-12-31 | |
| Director of Finance/CFO | - | - | |
Imen Charfeddine
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 88-12-31 | |
| Director of Finance/CFO | - | - | |
Salah Ben Turkia
BRD | Director/Board Member | - | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 7.17 | -0.14% | 2,521 |
| 24-05-02 | 7.18 | -0.28% | 3,315 |
| 24-04-30 | 7.2 | -0.69% | 1,859 |
| 24-04-29 | 7.25 | +0.42% | 3,882 |
| 24-04-26 | 7.22 | -0.28% | 297 |
End-of-day quote Tunis, May 02, 2024
More quotes
Unimed (Unité de Fabrication de Médicaments) is one of the leading pharmaceutical groups in Tunisia. The activity is organized around 2 families of products:
- generic medicines: primarily infusion and inhalation products, ophthalmic products, injectable liquids and powders;
- fashioned medicines: medicines manufactured for third parties.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.17
TND
Average target price
11.9
TND
Spread / Average Target
+65.97%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.14% | 73.1M | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| -3.40% | 157B |
- Stock Market
- Equities
- UMED Stock
